Blogs
Healthcare and Medtech Research Reports
Nov 13, 2026
Summary HER2 mutations are detected in approximately 1–5% of NSCLC patients, although the actual prevalence may be underestimated due to limited next-generation sequencing (NGS) adoption, particularly in community settings, where testing rates remain below 50%. The approval of AstraZeneca and Daiichi Sankyo’...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper